Introduction
============

In the past 6 years, genome-wide association studies (GWAS) have identified over 7,000 unique genetic loci associated with hundreds of complex traits and diseases \[[@b44]\]. Comprehensive analyses of these findings have found that GWAS signals are significantly overrepresented in regulatory regions of the genome \[[@b27]; [@b44]; [@b67]; [@b72]; [@b73]; [@b86]\]. Moreover, several follow-up functional studies have identified specific regulatory elements that underlie genetic associations and are directly implicated in complex disease etiology \[[@b33]; [@b42]; [@b71]; [@b77]; [@b93]\]. Although much of the focus on regulatory variation has been centered on transcriptional elements, such as promoters and long-range enhancers \[[@b23]\], a seminal study from the Georges lab in 2006 found the first example of a variant in a microRNA (miRNA) target site contributing to a disease phenotype (muscular hypertrophy in Texel sheep) \[[@b21]\]. Five years later, [@b15] identified the very first case of a human GWAS signal that may be explained by polymorphic miRNA targeting---a synonymous variant that alters a miR-196 target site and influences risk for Crohn's disease \[[@b35]\]. Following that report, another group implicated the miR-137 locus in [@b1], though the molecular mechanism underlying the association remains unclear. Most recently, in 2012, [@b81] demonstrated that a variant in the 3′-untranslated region (3′-UTR) of *lipoprotein lipase* (*LPL*) disrupts the binding of miR-410 and modulates the effect of diet on plasma lipid levels. These findings highlight the importance of expanding the view of the regulatory variation landscape beyond chromatin and transcriptional control elements.

miRNAs are short (∼22 nucleotide) noncoding RNAs that regulate gene expression principally at the posttranscriptional level \[[@b8]\]. The human genome encodes for over 1,000 miRNAs in either intragenic regions or independent transcription units \[[@b38]; [@b53]\]. miRNA loci are transcribed predominantly by RNA Polymerase II \[[@b17]; [@b56]\], yielding primary transcripts (pri-miRNAs) of highly variable length depending on the locus \[[@b84]; [@b93]\]. The pri-miRNA is processed within the nucleus by the ribonuclease Drosha and its cofactors, generating one or more precursor sequences (pre-miRNAs) with a hairpin-like secondary structure \[[@b51]; [@b52]\]. The pre-miRNA is then exported to the cytoplasm, where it is subject to further enzymatic processing by Dicer and its partners, producing a ∼22 bp double stranded RNA duplex. One strand of this duplex, referred to as the mature miRNA, is loaded onto the RNA-induced silencing complex (RISC). The miRNA guides and tethers the RISC to specific target RNAs to regulate their stability and/or translation \[[@b8]\].

The miRNA regulome (defined as the compendium of regulatory elements that either regulate miRNA expression or are regulated by miRNA activity) is a critical component of the biological networks that govern cellular and systemic phenotypes \[[@b34]; [@b60]; [@b98]\]. miRNAs have emerged as stable plasma biomarkers for disease diagnosis and prognosis \[[@b70]\], and as promising therapeutic targets for a growing number of disorders \[[@b48]; [@b97]\]. Recent studies of genetic variation in human populations demonstrated that purifying selection has constrained the genetic diversity of the miRNA Regulome \[[@b18]; [@b45]; [@b57]; [@b79]; [@b85]\]. In fact, Chen and Rajewsky reported in their seminal 2006 study that negative selection may be stronger on predicted conserved miRNA target sites than on most other functional classes of genomic elements, including nonsynonymous sites \[[@b18]\]. These findings suggest that genetic variation in the miRNA regulome may have strongly deleterious phenotypic consequences. Notably, however, several of the same studies also identified islands of the miRNA regulome that have been subject to recent positive selection \[[@b57]; [@b61]; [@b79]; [@b85]\]. Taken together, these observations indicate that genetic variation in the miRNA regulome contributes to both population adaptation and complex disease etiology.

Human genetic variation in the miRNA regulome, particularly miRNA target sites, has been extensively catalogued \[[@b6]; [@b10]; [@b37]; [@b41]; [@b43]; [@b54]; [@b87]; [@b100]\], and has been demonstrated to have widespread effects on miRNA-mediated gene regulation \[[@b32]; [@b50]; [@b63]\]. Although the extent to which polymorphic miRNA-mediated gene regulation contributes to phenotypic variation is not clear \[[@b90]\], it is an area that could have broad implications for disease biology \[[@b12]; [@b19]; [@b32]; [@b36]\] and pharmacogenomics \[[@b69]\] and as such, clearly merits further investigation.

Over the last 2 years, several bioinformatic strategies and web servers have been developed to facilitate the identification of validated GWAS signals that alter the miRNA regulome \[[@b5]; [@b16]; [@b58]; [@b80]; [@b96]; [@b99]\]. However, these approaches harbor several major limitations that hinder the effective prioritization of variants for functional validation. In this study, we present the most comprehensive strategy to date that addresses each of these limitations. We highlight specific findings and also discuss how the approach can be expanded in the future. We believe that the results of this study will be very valuable for researchers interested in determining whether GWAS signals implicate the miRNA regulome in their disease/trait of interest.

Materials and Methods
=====================

Defining Linkage Disequilibrium Blocks of Trait/Disease Association
-------------------------------------------------------------------

The NHGRI GWAS catalog (as of 11/14/12) was mined for all single nucleotide polymorphisms (SNPs) reported to be associated (*P* \< 1.0 × 10^−5^) with a trait/disease. For simplicity sake, multi-SNP haplotypes (*n* = 46) were not considered. For each study, the following information was recorded: first author, row number in GWAS catalog, PubMed ID, index SNP ID, trait/disease, case--control cohort ancestry, and association *P* value.

Each GWAS was assigned to one of four super-populations in the 1000 Genomes Project (1000G) according to the mapping scheme described in Box 1. For each index SNP reported in each GWAS, 1000G SNPs in linkage disequilibrium (LD) (defined as *r*^2^ \> 0.6) were identified by mining the 1000G phase I haplotype data for the assigned super-population (<http://www.sph.umich.edu/csg/yli/mach/download/1000G.2012-02-14.html>). For every SNP in an LD block of association, the following information from 1000G was recorded: chromosomal location (hg19), extent of LD with index SNP (*r*^2^), and minor allele identity/frequency in the assigned super-population.

### BOX 1. GWAS Assignments to One of Four Super-Populations of the 1000 Genomes Project

  Case--control cohort ancestry information provided by the GWAS                                                                                                                                                                                                                                                                                                                                      1000G super-population assignment
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------
  Indian\|India\|Europe\|Canadian\|Canada\|Caucasian\|White\|Framingham\|Norwegian\|Norway\|French\|France\|Iceland\|German\|Germany\|Scandanavia\|Finnish\|Finland\| UK \|Welsh\|Wales\|Irish\|Ireland\|Scottish\|Scotland\|Spanish\|Spain\|Iberia\|Toscani\|Tuscan\|Utah\|CEPH\|England\|English\|Swiss\|Switzerland\|Australia\|Turkish\|Turkey\|Saami\|Belgium\|Belgian\|Russia\|Polish\|Poland   EUR (European)
  Africa\|Ghani\|Malawi\|Yoruba\|Esan\|Mende\|Sierra\|Leone\|Gambia\|Kenya\|Luhyai                                                                                                                                                                                                                                                                                                                    AFR (African)
  Mexico\|Mexican\|Hispanic\|Peru\|Puerto\|Rico\|Rican\|Colombia\|Medellin\|Lima                                                                                                                                                                                                                                                                                                                      AMR (American)
  Asia\|Chin\|Japan\|Thai\|Korea\|Bangladesh\|Taiwan\|Indonesia\|Vietnam\|Hong Kong\|Kosrae\|Micronesia\|Papua New Guinea\|Han\|Dai\|Kinh \|Tokyo\|Xishuangbanna\|Beijing                                                                                                                                                                                                                             ASN (Asian)
  Anything else                                                                                                                                                                                                                                                                                                                                                                                       EUR (European)

miRNA Regulome Datasets
-----------------------

Human miRNA and pre-miRNA locations were downloaded from miRBase version 18 (<http://www.mirbase.org/>). Promoter regions of human miRNAs were obtained from epigenomic studies in two primary human cell types: CD4+ T cells \[[@b7]\] and pancreatic islets \[[@b93]\]. 3′-UTR sequences from the reference genomes of human, mouse, rat, dog, and chicken were downloaded from TargetScan 6.1 (<http://www.targetscan.org/cgi-bin/targetscan/data_download.cgi?db=vert_61>). Coordinates for the human 3′-UTR sequences were obtained by running a command line version of BLAT against the human genome (hg19). 3′-UTRs that mapped perfectly to multiple locations, or that appeared to be spliced, or were of length \<20 nt (BLAT requires sequences \>20 nt) were discarded from the analysis. For each 3′-UTR, the RefSeq ID provided by TargetScan 6.1 was converted to the official gene symbol using the BioMart database (<http://useast.ensembl.org/biomart/martview/>).

Human miRNA target sites were predicted within the reference 3′-UTR sequences using the TargetScanS algorithm (written in Perl and executed on a local server). For each prediction, the following information was recorded: miRNA name, gene symbol, target site type (7mer-1a, 7mer-m8, and 8mer-1a, in order of increasing efficacy), and a conservation number (1--5, indicating the number of species among \[human, mouse, rat, dog, chicken\] in which the putative target site is exactly conserved; a value of 1 indicates that the site is present only in the human and not in any of the other four species analyzed).

For each human 3′-UTR reference sequence, the allelic complement was generated by replacing every reference allele with the nonreference allele at each bi-allelic polymorphic locus reported by 1000G. If two or more SNPs are within the span of a target site (7 nt), all combinations of reference and alternate alleles at these sites were considered (e.g., if two A/T SNPs are within 7 nt, each of the potential AT, TA, and TT haplotypes would be considered). Many SNPs in close proximity are likely to be in strong LD; therefore, some of these allelic combinations are likely very rare. However, they have been included for comprehensiveness. Human miRNA target sites were predicted within the allelic complement 3′-UTR sequences using the TargetScanS algorithm. For each prediction, the same information as for predictions in the reference 3′-UTRs was recorded.

Other Functional Annotation Datasets
------------------------------------

Coding exons were downloaded from the "knownGenes" table on the UCSC Table Browser (<https://genome.ucsc.edu/cgi-bin/hgTables>).Nonsynonymous SNPs (nonsense, missense, frameshift) were downloaded from dbSNP build 137 (<ftp://ftp.ncbi.nih.gov/snp/organisms/human_9606/VCF/00-All.vcf.gz>).Transcriptional SNPs were downloaded from RegulomeDB (<http://regulome.stanford.edu/downloads>).Expression quantitative trait loci (eQTLs) in lymphocytes were obtained from (P.F. Sullivan, unpublished data).Validated miRNA:target-gene pairs were downloaded from TarBase 5.0 (<http://diana.cslab.ece.ntua.gr/tarbase/tarbase_download.php>).

Identification of Candidate miRNA Regulatory Hubs
-------------------------------------------------

Candidate gene lists for each trait/disease were extracted from the NHGRI GWAS catalog. For each trait/disease, potential miRNA regulatory hubs in the underlying gene network were identified by Monte Carlo simulation analysis. First, the seed-based TargetScanS algorithm was used to determine the number of predicted conserved targets in the gene list for each miRNA. This number was converted to a score by weighting 8-mer seed matches or target sites within 60 nt by a factor of 1.5. This procedure was repeated 100,000 times with a new set of randomly selected genes from the human genome each time, to generate a background expectation of the targeting score for each miRNA, which was then used to calculate an empirical *P* value for the score obtained with the candidate gene list for the trait/disease. To account for differences in the average 3′-UTR length between the trait/disease genes of interest and the randomly selected genes in each simulation, the number of predicted target genes was normalized to the average 3′-UTR length in the following manner. Specifically, the following equation is used: , where is the normalized number of predicted target genes in a random simulation, *T* is the actual number of predicted target genes in a random simulation, is the average length of the 3′-UTRs in the test set, and is the average length of the 3′-UTRs in the random set.

Results
=======

Strategy
--------

We developed an integrative genomic pipeline to catalog and prioritize trait/disease-associated single nucleotide polymorphisms (TASs) in the miRNA regulome. TASs include SNPs reported by GWAS (index SNPs) and all other SNPs in strong LD. We describe below five features of our strategy that represent conceptual and/or empirical advances relative to the existing approaches: *Inclusion of nonconserved miRNA target sites*. Current approaches have largely restricted their analyses to predicted miRNA target sites that are highly conserved. However, recent integrative genomic analyses indicate that GWAS loci are enriched in nonconserved regions of the genome \[[@b31]; [@b86]\]. Therefore, it is likely that overlooking lineage-specific miRNA target sites misses many causative variants. We have included in our pipeline any miRNA target site that is predicted in the human genome regardless of the extent of cross-species conservation (Methods).*Definition of LD blocks of association using data from the 1000 Genomes Project*. Current approaches compute LD using genotype data from the International HapMap project \[[@b4]\]. Instead, we have chosen to define LD blocks based on the sequence data from phase I of the 1000 Genomes Project (1000G) (Methods), because it provides the highest resolution human genetic map to date \[[@b2]\]. Specifically, compared with HapMap, the 1000G resource doubles the number of variants that are in LD with each GWAS index SNP \[[@b2]\].*Definition of population-specific LD blocks of association*. Current approaches consider only the LD structure in HapMap individuals of European descent. To account for the increasing number of GWAS in non-European populations and the varying LD patterns across different populations, we have defined LD blocks for each index SNP from each GWAS using the 1000G data for the "super population" (African, Asian, American, European) that most closely matches the ancestry of the case-control cohort used in the GWAS (Methods).*Inclusion of miRNA promoter regions*. Until recently, promoters of miRNAs were largely unknown and were not considered in most surveys of genetic variation in the miRNA regulome. In last few years, several groups, including our own, have used large-scale epigenomic strategies to annotate comprehensively the promoter regions of miRNAs \[[@b7]; [@b22]; [@b66]; [@b76]; [@b93]\]. Given that genetic variants in miRNA promoters could alter miRNA expression and function \[[@b65]\], and that gene promoters are enriched for GWAS loci \[[@b44]\], we have incorporated miRNA promoter annotations from two different studies into the analysis pipeline (Methods).*Functional annotation of all SNPs within LD association blocks to assess the likelihood that the association signal is explained by the miRNA regulome*. Current approaches do not assess whether the association signal is likely to be explained by a gene regulatory mechanism, and if it is, whether any of the genetic variants in the associated LD block may have other (non-miRNA-related) compelling regulatory annotations. Therefore, for every TAS in the miRNA regulome, we annotate whether any of the SNPs in the corresponding GWAS LD block occur at exons, nonsynonymous sites, and/or transcriptional regulatory elements as defined by RegulomeDB \[[@b13]\], which includes all of the high-throughput experimental datasets generated by the Encyclopedia of DNA Elements (ENCODE) Project\[[@b25]\]. TASs in LD blocks uniquely associated with the miRNA regulome (i.e., LD blocks that do not harbor any other exonic or transcriptional SNP) are deemed to be of highest priority for functional validation. Finally, for every candidate miRNA:trait pair that we identify, we perform a Monte Carlo simulation to determine whether the miRNA is a candidate regulatory hub in the network of genes implicated in the trait by GWAS.

Trait/Disease-Associated Genetic Variants in the miRNA Regulome
---------------------------------------------------------------

Our integrative analysis of the NHGRI GWAS catalog and the 1000G database identified 211,687 unique TASs ([Fig. 1](#fig01){ref-type="fig"}). Of these, 12, 41, and 2,041 TASs occur within miRNA precursors, miRNA promoter regions, and 3′-UTRs, respectively.

### miRNA precursors

The low density of TASs in pre-miRNAs is consistent with previous reports and is suggestive of negative selection on miRNA loci. Of the 12 TASs within pre-miRNAs, six are in GWAS LD blocks that do not contain any known exonic variant ([Fig. 1](#fig01){ref-type="fig"}). Among these six is rs12803915 ([Table 1](#tbl2){ref-type="table"}; Supp. Table S1), which is located within the precursor of a primate-specific miRNA (miR-612), and is in moderate LD (1000G EUR, *r*^2^ = 0.6) with a reported index SNP (rs17146964) for vertical cup-disc ratio (CDR; a parameter linked to glaucoma risk) in a case-control cohort of European ancestry. A very recent study demonstrated in several cell lines that the minor allele of rs12803915 significantly alters the cellular processing of pre-miR-612 and, consequently, the expression levels of mature miR-612 \[[@b49]\]. This pre-miRNA TAS is a compelling candidate for further validation as a determinant of CDR.

###### 

Selected Examples of Trait/Disease-Associated SNPs (TASs) in the miRNA Regulome

  Trait/disorder                     miRNA regulome SNP   Minor allele frequency   miRNA        miRNA regulome element
  ---------------------------------- -------------------- ------------------------ ------------ ------------------------
  Vertical cup-disc ratio            rs12803915           21.4% (EUR)              miR-612      Pre-miRNA
  Pulse rate                         rs6701558            11.2% (ASN)              miR-29b/c    Promoter region
  Schizophrenia                      rs2660302            21.8% (EUR)              miR-137      Promoter region
  Height                             rs113431232          3.4% (EUR)               let-7a/d/f   Promoter region
  Pigmentation                       rs35407              2.2% (EUR)               miR-27       *SLC45A2* target site
  Body mass index                    rs77632545           19.9% (ASN)              miR-181a     *ZNF169* target site
  Asthma                             rs17052784           2.6% (EUR)               miR-140-3p   *DCLK1* target site
  Plasma C-reactive protein levels   rs116971887          4.9% (EUR)               miR-194      *SALL1* target site
  Type 1 diabetes autoantibodies     rs3842753            50.0% (EUR)              miR-491-5p   *INS* target site
  Type 2 diabetes                    rs1802295            50.0% (ASN)              miR-510      *VPS26*A target site

Of the 42 TASs that are in the miRNA regulome and are not in LD with annotated nonsynonymous or transcriptional SNPs, 10 are shown here (pre-miRNA, *n* = 1; miRNA promoter, *n* = 3; miRNA target site, *n* = 6). Minor allele frequencies (MAFs) are specific to the 1000G super-population (ASN, Asian; EUR, European; AMR, American; AFR, African) that is closest to the ancestry of the case-control cohort in the GWAS that identified the genetic association. MAFs of the miRNA regulome SNPs range from relatively rare (e.g., rs35407, EUR MAF = 0.022) to very common (e.g., rs1802295, ASN MAF = 0.5).

### miRNA promoter regions

Of the 41 TASs within miRNA promoters, 16 are in GWAS LD blocks that do not contain any known exonic variant ([Fig. 1](#fig01){ref-type="fig"}). Among these 16 is rs6701558 ([Table 1](#tbl2){ref-type="table"}; Supp. Table S1), which is within the promoter of the miR-29b-2/miR-29c cluster, and is in complete LD (1000G ASN, *r*^2^ = 1) with a reported index SNP (rs12731740) for pulse rate in a cohort of Asian ancestry. This finding is consistent with the recent observation that the miR-29 family of miRNAs control aortic dilation and aneurysm formation \[[@b11]\], which directly influence heart rate. Another compelling candidate for functional evaluation is rs2660302 ([Table 1](#tbl2){ref-type="table"}; Supp. Table S1), which occurs within the promoter of miR-137, and is in LD (1000G EUR, *r*^2^ = 0.71) with an index SNP (rs1625579) for schizophrenia in a cohort of European ancestry. Two previous studies demonstrated that miR-137 is a candidate regulatory hub in the schizophrenia gene network \[2011; [@b78]\]. The rs2660302 locus may mediate allele-dependent transcriptional regulation of miR-137, thereby altering the expression status of genes underlying the etiology of schizophrenia.

To identify the most compelling functional candidates among the remaining 15 miRNA promoter TASs, we implemented a Monte Carlo simulation strategy to determine for each of the 15 miRNA:trait pairs whether the miRNA is predicted to target significantly more of the protein-coding genes implicated in the trait by GWAS than expected by chance. The most striking result was for the pair let-7:height ([Fig. 2](#fig02){ref-type="fig"}A). Specifically, we found that predicted target sites for let-7 are the most significantly overrepresented within the 3′-UTRs of genes at loci associated with human stature ([Fig. 2](#fig02){ref-type="fig"}A). The TAS (rs113431232) located within the let-7 promoter region has a minor allele frequency (MAF) of ∼3% in the 1000G population of European ancestry and is in LD (1000G EUR, *r*^2^ = 0.74) with a reported index SNP (rs1257763) for height ([Table 1](#tbl2){ref-type="table"}; Supp. Table S1). We mined the ENCODE database and determined that this TAS occurs within a region of open chromatin in many cell types ([Fig. 2](#fig02){ref-type="fig"}B), highlighting the possibility that it may influence the transcriptional activity of the locus. We then analyzed the ENCODE data generated by chromatin immunoprecipitation followed by high-throughput sequencing (ChIP-seq) and found that the TAS overlaps a high-confidence binding site in HeLa cells for the transcription factor E2F4 ([Fig. 2](#fig02){ref-type="fig"}B). Notably, a recent study validated this binding site by ChIP-PCR and also demonstrated that overexpression of E2F4 in HeLa cells leads to down-regulation of let-7 \[[@b55]\]. This finding is consistent with the known oncogenic and tumor suppressive capacity of E2F4 and let-7, respectively \[[@b9]; [@b83]\]. The minor allele at rs113431232 may disrupt E2F4 binding, thereby upregulating let-7 and altering the expression of targets that influence cell growth and, ultimately, human stature.

![Summary of the analysis pipeline. The primary data sources (pink rectangles) and the number of trait-associated SNPs (blue rectangles) passing each filter (red text) in the analysis pipeline are shown. ^\*^, candidate miRNA regulatory hubs are identified for each trait/disease using a Monte Carlo simulation strategy (Methods).](humu0034-1049-f1){#fig01}

![A genetic variant in the let-7 promoter may contribute to human height variation. A: Each data point represents a human miRNA and the y-axis shows the log10 of the *P* value of miRNA target site enrichment among genes implicated in height by GWAS. The dashed line denotes the significance threshold (empirical *P* = 0.01). B: SNP rs113431232, which is in LD with an index SNP (rs1257763) for height, occurs in a validated E2F4 binding site within the promoter region of the let-7a/d/f miRNA cluster. H3K4me3 (histone H3 lysine 4 tri-methylation) ChIP-seq signal (ENCODE) denotes promoter regions; DNase HS (DNase I hypersensitive site) signal (ENCODE) denotes open chromatin; E2F4 ChIP-seq signal (ENCODE) denotes chromatin occupancy of transcription factor E2F4. Peak E2F4 occupancy signal (red rectangle) occurs within a local dip in the DNase HS signal, which is indicative of a bound transcription factor(s). All ENCODE data shown are from HeLa cells.](humu0034-1049-f2){#fig02}

### miRNA target sites

Of the 2,041 TASs located in 3′-UTRs, 1,763 create and/or abolish predicted target sites for human miRNAs ([Fig. 1](#fig01){ref-type="fig"}; Supp. Table S2). One of these, rs13702, has recently been validated by rigorous follow-up genetic and molecular studies \[[@b81]\]. Specifically, [@b81] demonstrated that the rs13702 minor allele reduces plasma lipid levels by abolishing a miR-410 target site in the 3′-UTR of *LPL*, which leads to increased LPL expression and activity. Two other TASs, rs12537 and rs12904, which are associated with IgA nephropathy and gamma-glutamyl transferase (GGT) levels, respectively, have been implicated previously in gastric cancer by candidate gene association studies. *In vitro* molecular experiments have confirmed that the rs12537 minor allele creates a miR-181a target site in *MTMR3* \[[@b62]\] and that the rs12904 minor allele disrupts a highly conserved miR-200bc target site in *EFNA1* \[[@b59]\]. However, neither has yet been verified as the mechanistic link for the genetic association with IgA nephropathy and GGT levels, respectively. Although both rs12537 and rs12904 are in strong LD with nonsynonymous variants and SNPs in predicted transcriptional regulatory elements (Supp. Table S2), the miRNA-related mechanism may merit further investigation. We performed an analysis of TarBase 5.0, a repository of experimentally supported miRNA:target-gene pairs (Methods), and identified one additional TAS (rs891368) that occurs within a predicted miRNA target site for a gene (*RFT1*) that has been previously demonstrated to be regulated by the same miRNA (miR-15). rs891368 is in perfect LD (*r*^2^ = 1) with a reported index SNP (rs2336725) for height (Supp. Table S2).

Among the 1,763 TASs within miRNA target sites, 42 are in GWAS LD blocks that do not contain either a nonsynonymous or a transcriptional regulatory variant ([Fig. 1](#fig01){ref-type="fig"}; Supp. Table S2). Of these, 26 are either in very strong LD (*r*^2^ \> 0.9) with the reported index SNPs or are the index SNPs themselves. Several such TASs are highlighted in [Table 1](#tbl2){ref-type="table"}, two of which are described in further detail below.

The minor allele at rs116971887 disrupts a highly conserved predicted miR-194 target site within the gene *SALL1*, and is in strong LD (1000G EUR, *r*^2^ = 0.92) with a reported index SNP for plasma C-reactive protein (CRP) levels ([Table 1](#tbl2){ref-type="table"}; Supp. Table S2), which is a strong indicator of cardio-metabolic status \[[@b75]\]. SALL1 is critical for normal development and function of the kidney \[[@b3]; [@b74]\], where miR-194 expression is highly enriched \[[@b89]\]. CRP is produced in the kidney in response to inflammatory signals \[[@b47]\] and is associated with abnormalities in kidney function \[[@b94]\]. The minor allele at rs116971887 is predicted to abrogate the miR-194 target site, thereby potentially increasing SALL1 expression levels. The question of whether this would lead to increased plasma CRP merits further detailed experimentation.

The minor allele at rs77632545 is predicted to create a new target site for miR-181a within the 3′-UTR of *ZNF169*, and is in strong LD (1000G ASN, *r*^2^ = 0.95) with a reported index SNP for body mass index (BMI). *ZNF169* is a member of the zinc-finger family of genes, which have been identified as harboring unusually effective coding region target sites specifically for miR-181a \[[@b46]; [@b88]\]. It has also been demonstrated that when miRNAs bind to messenger RNAs in both the coding region and the 3′-UTR the repressive effect on protein expression is synergistic \[[@b28]\]. Therefore, by creating a new miR-181a target site, the minor allele at rs77632545 could induce significantly decreased levels of ZNF169. Further investigation is required to determine whether altered expression of ZNF169 is associated with, or can directly influence, BMI and related phenotypes.

Discussion
==========

We have developed the most comprehensive approach to date for cataloging trait/disease-associated genetic variation in the miRNA regulome. Our analysis pipeline provides a concrete means of prioritizing variants in the miRNA regulome as functional candidates in GWAS. We described here specific miRNA-related variants that may explain genetic associations with a variety of traits/diseases, including body mass index, IgA nephropathy, and schizophrenia.

Our study is the first to catalog systematically trait/disease-associated genetic variants in miRNA promoter regions. These promoters were obtained from epigenomic analyses conducted in two different human cell types \[[@b7]; [@b93]\]. In future genetic analyses of the miRNA regulome, it will be meaningful to include a more comprehensive set of miRNA promoters, which can be identified by analyzing relevant chromatin data that have been generated by the ENCODE and NIH Epigenomics Roadmap consortiums for a wide array of different cell types and physiologic conditions. Furthermore, the application of chromosome conformation capture technology may facilitate the identification of long-range regulatory elements (e.g., enhancers and silencers) that contribute to the control of miRNA expression, and may also harbor trait/disease-causing genetic variants.

In our survey, we included the broadest set to date of predicted miRNA target sites based on an algorithm that identifies sequences within 3′-UTRs that are exactly complementary to the 5′-end of a miRNA, referred to as the "seed" region \[[@b30]\]. It has been demonstrated that some miRNAs have alternative modes of target recognition that do not require a seed match \[[@b14]; [@b20]; [@b92]\]. Also, miRNAs can effectively target regions outside the 3′-UTR, including the open reading frame \[[@b29]\]. Incorporating these categories of target sites will expand the functional miRNA regulome and facilitate the identification of trait/disease associated genetic variants that disrupt miRNA activity.

It is worth noting that variants beyond the miRNA regulome can still affect miRNA activity. For example, it has been demonstrated that 3′-UTR variants outside of a miRNA target site can influence miRNA targeting efficacy \[[@b68]\], potentially by altering local secondary structure and accessibility to the miRNA-RISC \[[@b39]\]. It is well established that genetic variants can alter mRNA folding \[[@b91]\], which in turn can influence function \[[@b40]\]. Very recently, high-throughput approaches have been developed to resolve RNA structures \[[@b24]; [@b64]\] toward the goal of predicting the effect of specific variants on secondary and tertiary RNA conformation \[[@b82]\]. As these strategies become increasingly tractable, it will be of great interest to assess the extent to which trait/disease-associated genetic variants that are not explicitly within the miRNA regulome nevertheless disrupt miRNA activity.

In summary, our strategy improves upon the accuracy and resolution of previous approaches and, importantly, facilitates the prioritization of genetic variants in the miRNA regulome as functional candidates in GWAS. Although we do not provide experimental validation in this study, we have highlighted specific examples that merit further detailed investigation, including a SNP associated with height that occurs within a validated E2F4 binding site in the let-7 promoter, and a SNP associated with vertical CDR that has been shown to alter miR-612 biogenesis. The bioinformatic pipeline presented in this study can be extended in the future to incorporate many other types of genomic data, such as miRNA expression patterns and somatic mutations in cancer.

Complex diseases are increasingly viewed as "network disorders" \[[@b95]\]. Biological networks often have mechanisms for conferring robustness against genetic and/or environmental perturbation, in part due to a web of miRNA activity \[[@b26]\]. Therefore, genetic variants that alter miRNA activity will likely have a dramatic effect on network output. We expect that as more high-powered genetic association studies are performed, and as the functional miRNA regulome is brought into clearer view, an increasing number of miRNA-related variants will be implicated in complex disease etiology.
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